Article
Public, Environmental & Occupational Health
Richeek Pradhan, Elisabetta Patorno, Helen Tesfaye, Sebastian Schneeweiss, Hui Yin, Jessica Franklin, Ajinkya Pawar, Christina Santella, Oriana H. Y. Yu, Christel Renoux, Laurent Azoulay
Summary: The study compared GLP-1 receptor agonists users with different active comparator groups and found a modestly increased risk of anaphylactic reaction associated with GLP-1 RAs.
AMERICAN JOURNAL OF EPIDEMIOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Yi-Hsin Chan, Tze-Fan Chao, Shao-Wei Chen, Hsin-Fu Lee, Pei-Ru Li, Wei-Min Chen, Yung-Hsin Yeh, Chi-Tai Kuo, Lai-Chu See, Gregory Y. H. Lip
Summary: The study evaluated the risk of new-onset AF associated with SGLT2i, GLP-1RA, and DPP4i in patients with type 2 diabetes, and found that SGLT2i, but not GLP-1RA, was associated with a lower incidence of AF compared to DPP4i.
CARDIOVASCULAR DIABETOLOGY
(2022)
Article
Gastroenterology & Hepatology
Santo Colosimo, Federico Ravaioli, Maria L. Petroni, Lucia Brodosi, Francesca Marchignoli, Francesca A. Barbanti, Anna S. Sasdelli, Giulio Marchesini, Loris Pironi
Summary: The study showed that GLP-1 receptor agonists and SGLT-2 inhibitors can improve biomarkers of steatosis and fibrosis, therefore slowing down the progression of liver disease.
LIVER INTERNATIONAL
(2021)
Article
Cardiac & Cardiovascular Systems
Carolyn S. P. Lam, Chinthanie Ramasundarahettige, Kelley R. H. Branch, Naveed Sattar, Julio Rosenstock, Richard Pratley, Stefano Del Prato, Renato D. Lopes, Elisabeth Niemoeller, Nardev S. Khurmi, Seungjae Baek, Hertzel C. Gerstein
Summary: The analysis of the AMPLITUDE-O trial suggests that the efficacy and safety of Efpeglenatide are not impacted by concurrent use of SGLT2 inhibitors. These data support the combined use of SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes.
Article
Pharmacology & Pharmacy
Andreana Foresta, Luisa Ojeda-Fernandez, Giulia Macaluso, Maria Carla Roncaglioni, Mauro Tettamanti, Ida Fortino, Olivia Leoni, Stefano Genovese, Marta Baviera
Summary: This study assessed the effect of dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) on COVID-19-related outcomes. The results showed a reduced risk of COVID-19 total mortality in DPP-4i users compared with nonusers. Additionally, GLP-1 RA users had a lower hospital admission rate and SGLT-2i users had a lower in-hospital mortality rate compared with nonusers. Randomized clinical trials are needed to confirm the potential therapy of these drug classes for COVID-19 treatment.
CLINICAL THERAPEUTICS
(2023)
Review
Cardiac & Cardiovascular Systems
Pierre Gourdy, Patrice Darmon, Francois Dievart, Jean-Michel Halimi, Bruno Guerci
Summary: GLP-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) have shown cardiovascular protective effects, making them breakthrough therapies for type 2 diabetes mellitus (T2DM). This review discusses the synergies between GLP-1RAs and SGLT2is, highlighting their benefits in treating metabolic-cardiovascular-renal disease in T2DM patients. While SGLT2is have stronger evidence for renal effects, GLP-1RAs are preferable as add-on therapy for T2DM patients with chronic kidney disease and persistent albuminuria or uncontrolled metabolic risks. However, factors such as reimbursement and costs may delay the widespread use of combination therapy. An individualized approach should be taken when considering GLP-1RA plus SGLT2i combination therapy, taking into account individual preferences, costs, toxicity profile, kidney function, glucose-lowering efficacy, weight loss goals, and comorbidities.
CARDIOVASCULAR DIABETOLOGY
(2023)
Review
Behavioral Sciences
Che-Yuan Wu, Lila Shapiro, Michael Ouk, Bradley J. MacIntosh, Sandra E. Black, Baiju R. Shah, Walter Swardfager
Summary: Type 2 diabetes is a major risk factor for dementia. Different glucose-lowering drugs have different effects on the brain. The current clinical and epidemiological data are mixed, requiring careful evaluation. Personalized strategies using glucose-lowering drugs have great potential in preventing and treating dementia.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
(2022)
Article
Pharmacology & Pharmacy
Yen-Chieh Lee, Yaa-Hui Dong, Wei-Shun Yang, Li-Chiu Wu, Jou-Wei Lin, Chia-Hsuin Chang
Summary: The study found that the use of SGLT-2i in patients with type 2 diabetes does not increase the risk of hospitalization for limb events compared to GLP-1RA. However, a trend of higher LEA risk was observed among SGLT-2i users with a history of cardiovascular disease.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Endocrinology & Metabolism
Kasper B. Kristensen, Daniel P. Henriksen, Jesper Hallas, Anton Pottegard, Lars C. Lund
Summary: Initiation of treatment with SGLT2Is was associated with a clinically significant reduced risk of incident and recurrent nephrolithiasis.
Article
Cardiac & Cardiovascular Systems
Marta Baviera, Andreana Foresta, Pierluca Colacioppo, Giulia Macaluso, Maria Carla Roncaglioni, Mauro Tettamanti, Ida Fortino, Stefano Genovese, Irene Caruso, Francesco Giorgino
Summary: This study compared the effectiveness and safety of GLP-1 RA and SGLT-2i in a large cohort of patients with type 2 diabetes. The results showed that GLP-1 RA was equally safe but more effective than SGLT-2i in reducing the risk of major adverse cardiovascular events and non-fatal myocardial infarction. The incidence of serious adverse events was low in both treatment groups.
CARDIOVASCULAR DIABETOLOGY
(2022)
Review
Endocrinology & Metabolism
Yijun Li, Ying Hu, Xiaoyuan Huyan, Kang Chen, Bing Li, Weijun Gu, Yiming Mu
Summary: The study aims to analyze the efficacy and safety of three novel hypoglycemic agents, GLP-1 RAs, DPP-4i, and SGLT2i, in T2DM patients with severe CKD. The results show that SGLT2i performs better than placebo and DPP-4i in reducing the incidence of severe renal-related adverse events and renal death. Compared to placebo, SGLT2i also significantly reduces the incidence of all-cause death and severe adverse events, while DPP-4i significantly reduces HbA1c levels.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Medicine, Research & Experimental
Cristina Bouzas, Rosario Pastor, Silvia Garcia, Margalida Monserrat-Mesquida, Miguel Angel Martinez-Gonzalez., Jordi Salas-Salvado, Dolores Corella, Albert Goday, J. Alfredo Martinez, Angel M. Alonso-Gomez, Olga Fernandez-Barcelo, Jesus Vioque, Dora Romaguera, Jose Lopez-Miranda, Ramon Estruch, Francisco J. Tinahones, Jose Lapetra, Lluis Serra-Majema, Blanca Riquelme-Gallegop, Vicente Martin-Sanchez, Xavier Pinto, Miguel Delgado-Rodriguez, Pilar Matia, Josep Vidal, Jersy-Jair Cardenas-Salas, Lidia Daimiel, Emilio Ros, Estefania Toledo, Josep M. Manzanares, Inmaculada Gonzalez-Monge, Miguel-Angel Munoz, Diego Martinez-Urbistondo, Lucas Tojal-Sierra, Carlos Munoz-Bravoaf, Salvador Miralles-Gisbert, Marian Martin, Antonio Garcia-Rios, Sara Castro-Barquero, Jose Carlos Fernandez-Garcia, Jose Manuel Santos-Lozano, F. Javier Basterra-Gortari, Liliana Gutierrez-Carrasquilla, Patricia Guillem-Saiz, Alba Satorres, Itziar Abete, Carolina Sorto-Sanchez, Javier Diez-Espino, Nancy Babio, Montse Fito, Josep A. Tur
Summary: In a one-year study involving 6881 patients with MetS, it was found that those treated with GLP-1RA and DPP-4I had better glycemic profiles, but improvements in weight and waist circumference were modest.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Endocrinology & Metabolism
Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Hiroyuki Sakai, Takayuki Furuki, Keiichi Chin, Moritsugu Kimura, Nobumichi Saito, Tomohiko Kanaoka, Togo Aoyama, Tomoya Umezono, Shun Ito, Daisuke Suzuki, Hiroshi Takeda, Fuyuki Minagawa, Hisakazu Degawa, Hideo Machimura, Toshimasa Hishiki, Shinichi Umezawa, Hidetoshi Shimura, Shinichi Nakajima, Hareaki Yamamoto, Kazuyoshi Sato, Masaaki Miyakawa, Yasuo Terauchi, Kouichi Tamura, Akira Kanamori
Summary: By comparing the effects of SGLT2i and GLP1Ra treatments on patients with type 2 diabetes, this study found that the renal composite outcome incidence was lower in the SGLT2i-treated group, with smaller changes in eGFR.
DIABETES RESEARCH AND CLINICAL PRACTICE
(2022)
Review
Urology & Nephrology
Nuria Montero, Laia Oliveras, Maria Jose Soler, Josep Maria Cruzado
Summary: PTDM is a common issue after kidney transplantation, affecting 50% of high-risk recipients. KDIGO has updated guidelines for diabetes management in CKD, focusing on newer antidiabetic agents. Generating evidence is necessary to safely use these treatments and evaluate their potential cardiovascular and renal benefits in PTDM patients.
CLINICAL KIDNEY JOURNAL
(2022)
Review
Pharmacology & Pharmacy
Haiying Cui, Yao Wang, Shuo Yang, Guangyu He, Zongmiao Jiang, Xiaokun Gang, Guixia Wang
Summary: This study assessed the associations between antidiabetic medications (ADM) and the risk of prostate cancer (PCa) in diabetics. The results indicate that the use of thiazolidinediones and glucagon-like peptide-1 receptor agonists (GLP-1RA) may reduce the risk of PCa.
PHARMACOLOGICAL RESEARCH
(2022)
Review
Biochemistry & Molecular Biology
Jelena Vekic, Sanja Vujcic, Biljana Bufan, Dragana Bojanin, Khamis Al-Hashmi, Khaild Al-Rasadi, Anca Pantea Stoian, Aleksandra Zeljkovic, Manfredi Rizzo
Summary: Insulin resistance often leads to disorders of lipoprotein metabolism and glucose homeostasis, which are common in patients with metabolic syndrome and type 2 diabetes mellitus. Insulin-resistant subjects have a specific lipid pattern called atherogenic dyslipidemia, characterized by hypertriglyceridemia, reduced high-density lipoprotein cholesterol level, and increased proportion of small, dense low-density lipoprotein. Chronic hyperglycemia promotes non-enzymatic glycation, resulting in increased production of advanced glycation end products (AGEs).
Article
Medical Laboratory Technology
Daniela Ligi, Bruna Lo Sasso, Chiara Della Franca, Rosaria Vincenza Giglio, Luisa Agnello, Marcello Ciaccio, Ferdinando Mannello
Summary: The study investigated the role of extracellular histones on monocyte distribution width (MDW) and their effect on the release of cytokines by blood cells. The results showed that extracellular histones can induce changes in MDW and promote heterogeneity in monocytes. They also lead to the release of cytokines, especially G-CSF, IL-1 beta, IL-6, MIP-1 beta, and IL-8. These findings may have significant implications for predicting the risk of severe outcomes.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2023)
Review
Biochemistry & Molecular Biology
Teodor Salmen, Liviu-Ionut Serbanoiu, Ioana-Cristina Bica, Cristian Serafinceanu, Emir Muzurovic, Andrej Janez, Stefan Busnatu, Maciej Banach, Ali Abbas Rizvi, Manfredi Rizzo, Anca Pantea Stoian
Summary: The increase in life expectancy has led to a rise in the elderly population prone to polypharmacy. Novel antidiabetic drugs, such as DPP-4i, SGLT-2i, GLP-1 Ra, and tirzepatide, can effectively address this health issue in patients with diabetes mellitus. However, further research is needed to determine their exact efficacy and safety profiles.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Ioana-Cristina Bica, Valeria-Anca Pietrosel, Teodor Salmen, Cosmina-Theodora Diaconu, Carmen Fierbinteanu Braticevici, Roxana-Adriana Stoica, Andra Iulia Suceveanu, Anca Pantea Stoian
Summary: As the understanding of the pathophysiologic mechanisms of type 2 diabetes mellitus (T2DM) grows, a more patient-centered approach to management is being adopted, considering the interlink between T2DM and its complications. Sodium-glucose cotransporter 2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) show promise in reducing cardiovascular (CV) risk and improving metabolic control. Research is also accumulating on the modification of gut microbiota by these drugs, which play a significant role in the relation between diet and CV disease. Further research is needed to explore the individual and cumulative effects of these antidiabetic drugs on gut microbiota.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Medicine, General & Internal
Ioana Paunica, Marina Giurgiu, Anca Silvia Dumitriu, Stana Paunica, Anca Mihaela Pantea Stoian, Maria-Alexandra Martu, Cristian Serafinceanu
Summary: Periodontitis is caused by dental plaque and has a bidirectional relationship with diabetes. Diabetes worsens periodontal disease, while periodontitis negatively affects glycemic control. This review summarizes the pathogenesis, therapy, and prophylaxis of these two interconnected diseases.
Article
Biochemistry & Molecular Biology
Angelo Maria Patti, Rosaria Vincenza Giglio, Alberto Allotta, Andreina Bruno, Tommaso Di Bella, Anca Pantea Stoian, Marcello Ciaccio, Manfredi Rizzo
Summary: This retrospective observational study in Italy found that injectable semaglutide improved carotid intima-media thickness and hemoglobin A1c levels in type 2 diabetes patients. It also reduced cardiovascular risk factors and the triglyceride/high-density lipoprotein ratio. The study suggests the effect of semaglutide on atherosclerosis as a key cardiovascular protective mechanism.
Review
Biochemistry & Molecular Biology
Bianca-Margareta Salmen, Valeria-Anca Pietrosel, Cristiana-Elena Durdu, Teodor Salmen, Cosmina Theodora Diaconu, Ioana-Cristina Bica, Claudia Gabriela Potcovaru, Florentina Gherghiceanu, Roxana-Adriana Stoica, Anca Pantea Stoian
Summary: The prevalence of gestational diabetes mellitus (GDM) has increased, calling for non-invasive and precise techniques to assess the risk factors such as visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT). A systematic review identified 11 relevant articles that favored using US-determined VAT in predicting GDM. VAT may be more valuable than body mass index or SAT in GDM prediction, and can be utilized in conjunction with other parameters or risk factors. However, US measurements are heterogeneous and the lack of a gold standard for GDM identification poses a limitation.
Review
Biology
Dragos Serban, Ana Maria Dascalu, Andreea Letitia Arsene, Laura Carina Tribus, Geta Vancea, Anca Pantea Stoian, Daniel Ovidiu Costea, Mihail Silviu Tudosie, Daniela Stana, Bogdan Mihai Cristea, Vanessa Andrada Nicolae, Corneliu Tudor, Andreea Cristina Costea, Meda Comandasu, Mihai Faur, Ciprian Tanasescu
Summary: Diabetic retinopathy is a major cause of blindness and is associated with changes in gut microbiota, including altered Firmicutes/Bacteroidetes ratio, reduced butyrate producers, and increased pro-inflammatory species. The dysbiosis in gut microbiota may contribute to endothelial dysfunction and altered retinal metabolism. Understanding the gut-retina axis and targeting the gut microbiota could lead to new therapeutic strategies for treating diabetic retinopathy.
Article
Biology
Teodor Salmen, Florin-Teodor Bobirca, Ioana-Cristina Bica, Doina-Andrada Mihai, Corina Pop, Anca Pantea Stoian
Summary: The safety of SGLT2i and GLP-1 RAs in conjunction with other glucose-lowering drugs was evaluated. The results demonstrated that the combination of SGLT2i and GLP-1 RAs with other medications is safe for the management of type 2 diabetes mellitus.
Article
Biochemistry & Molecular Biology
Teodor Salmen, Ali Abbas Rizvi, Manfredi Rizzo, Valeria-Anca Pietrosel, Ioana-Cristina Bica, Cosmina Theodora Diaconu, Claudia Gabriela Potcovaru, Bianca-Margareta Salmen, Oana Andreia Coman, Anca Bobirca, Roxana-Adriana Stoica, Anca Stoian
Summary: In this retrospective study, both SGLT-2i and GLP-1 RAs showed efficacy in weight control, metabolic control, and diastolic blood pressure control when used in conjunction with other glucose-lowering, antihypertensive, and lipid-lowering medications in a real-life setting.
Review
Medicine, General & Internal
Ioana-Cristina Bica, Roxana Adriana Stoica, Teodor Salmen, Andrej Janez, Spela Volcansek, Djordje Popovic, Emir Muzurovic, Manfredi Rizzo, Anca Pantea Stoian
Summary: Type 2 Diabetes Mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) are part of metabolic syndrome and have multiple causal associations. Sodium-glucose cotransporter 2-inhibitors (SGLT2-i) have been studied for their effects on steatosis and fibrosis improvement in patients with NAFLD/NASH. This systematic review found that SGLT2-i agents, such as dapagliflozin, empagliflozin, and canagliflozin, showed efficacy in treating patients with NAFLD/NASH by addressing different pathophysiological targets/mechanisms. These findings suggest that SGLT2-i class may be considered as a top therapeutic option for patients diagnosed with T2DM and NAFLD/NASH.
MEDICINA-LITHUANIA
(2023)
Article
Health Care Sciences & Services
Stefan-Sebastian Busnatu, Octavian Andronic, Maria-Alexandra Pana, Anca Pantea Stoian, Alexandru Scafa-Udriste, Nicolae Paun, Silviu Stanciu
Summary: This study investigates the effects of oral supplementation with arginine on blood pressure in individuals performing resistance exercise training. The results show that supplementation with arginine can lower blood pressure, improve body composition, and serve as an adjuvant for regular resistance training.
Letter
Endocrinology & Metabolism
Djordje S. S. Popovic, Anca Pantea Stoian, Nikolaos Papanas
Article
Endocrinology & Metabolism
Luisa Agnello, Rosaria Vincenza Giglio, Bruna Lo Sasso, Matteo Vidali, Silvia Pedone, Davide Massa, Anna Maria Ciaccio, Caterina Maria Gambino, Marcello Ciaccio
ACTA DIABETOLOGICA
(2023)
Article
Medicine, Research & Experimental
Bruna Lo Sasso, Luisa Agnello, Rosaria Vincenza Giglio, Concetta Scazzone, Davide Massa, Anna Maria Ciaccio, Caterina Maria Gambino, Matteo Vidali, Marcello Ciaccio
Summary: Serology surveillance of SARS-CoV-2 antibodies is a valuable tool for monitoring protective immunity in the population. This study compared the performance of three different serological immunoassays for detecting anti-SARS-CoV-2 antibodies in 600 vaccinated subjects. The results showed that all three assays can effectively detect post-vaccine humoral immune response. The methods also demonstrated high specificity and correlation, making them suitable for monitoring IgG titers over time in vaccinated individuals.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)